These observations provide experimental evidence supporting that PNS or its major activity components Rg1, Rb1 and R1 could be considered as candidate drugs for further development to manage complex disease conditions such as cancer combined with cardiovascular disease. This evidence concerns the gene PPP1R3A and cancer.